Projected to expand by 10.2% in 2025, driven by front-loaded pharmaceutical exports ahead of US tariffs, real GDP growth will slow to 2.1% in 2026, reflecting the unwinding of these effects and higher trade barriers, before strengthening to 2.8% in 2027, as uncertainty eases somewhat. Supported by continued, though moderating job creation, domestic demand, net of the most volatile multinational activities, is projected to grow by 3.7% in 2025, 2.3% in 2026 and 2.6% in 2027.
A binding domestic fiscal rule will be key to ensure sustainable public finances over the medium-term. Tax receipts are projected to rise but will remain vulnerable to sudden reversals, were additional tariffs to reduce large multinationals’ earnings. Enhancing SMEs’ access to innovation and technology-adoption support, together with eased restrictions in legal services, could strengthen productivity growth and reduce cost pressures on businesses.